Food and Drug Administration logo

Food and Drug Administration logo (Photo credit: Wikipedia)

Against the recommendation of its own advisors, the U.S. Food and Drug Administration approved a new high-dose narcotic painkiller, a drug that the FDA concedes has a high risk for abuse and one which was using a method that critics say may give the drug the appearance of greater efficacy.

 

Zohydro ER will be the first hydrocodone-only opioid, and it will come in doses packing five to 10 times more heroin-like narcotic than traditional hydrocodone products such as Vicodin that combine hydrocodone with over-the-counter pain relievers such as acetaminophen or ibuprofen.

 

Abuse Potential

 

Though the narcotic in Zohydro ER is designed to be released slowly over 12 hours, pleasure seekers will be able to crush it, chew it or mix it with alcohol to unleash its full punch at once. That abuse potential would have been blunted if the FDA required that the drug be formulated with abuse-prevention technology — a process the FDA has publicly backed, but did not require in this case.

 

Complete article Here:

FDA and Opioids: What’s Going On Here?

 

 

 

Enhanced by Zemanta
Share
Share